Specify a stock or a cryptocurrency in the search bar to get a summary
Novacyt
ALNOVNovacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, France, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, and Yourgene Health segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The company was incorporated in 2006 and is based in Eastleigh, the United Kingdom. Address: York House, Eastleigh, United Kingdom, SO53 4DG
Analytics
WallStreet Target Price
3.9 EURP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ALNOV
Dividend Analytics ALNOV
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ALNOV
Stock Valuation ALNOV
Financials ALNOV
Results | 2019 | Dynamics |